Ciprofloxacin approved Aug. 30 by FDA for the post-exposure prophylaxis of anthrax. As its Phase IV commitment Bayer will assist federal agencies in analyzing data in the event of an anthrax outbreak. Bayer is in discussions with the Centers for Disease Control & Prevention and the Department of Defense regarding Cipro stockpiling. The new indication will cover Cipro tablets, oral suspension and I.V. formulations
You may also be interested in...
Virtual Drug Development, Inc. is seeking to develop a pre-exposure prophylactic antibiotic for Bacillus anthracis that could serve as an alternative to the current anthrax vaccine.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011